secwatch.observer — SEC 8-K summary
======================================

Issuer:     GeneDx Holdings Corp. (WGS)
CIK:        0001818331
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001818331-22-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sema4 Q1 2022: revenue $53.9M, net loss $76.9M; closes GeneDx acquisition, raises cash burn savings to $50M
--------------------------------------------------------------------------------

- Total revenue $53.9M (incl. COVID-19); ex-COVID revenue $50.1M, up 4% YoY.
- Adjusted gross margin 13%, up ~1,300 bps sequentially; net loss $76.9M, adjusted net loss $65.5M.
- Completed GeneDx acquisition in April; $200M private placement closed with Pfizer among investors.
- Reaffirms FY2022 pro forma revenue target $350M; total revenue guidance $305-315M.
- Cash $315M as of March 31; expects to reduce 2022 cash burn by $50M, extending runway into 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000044/0001818331-22-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818331/000181833122000044/smfr-20220512.htm
  HTML page:      https://secwatch.observer/filing/0001818331-22-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer